NTIDs with high variability [Design Issues]

posted by ioanam – Romania, 2010-06-07 15:52 (5449 d 04:12 ago) – Posting: # 5452
Views: 10,173

Which is the most appropriate design for a narrow therapeutic index drug with very high intra-subject variability?

For example, we have an immunosuppressive agent with an intra-subject CV% > 45%.
Using a standard two – way crossover design with acceptance interval tightened (90.00 – 111.11%), we will have a sample size of more than 300 subjects :-(.

It is possible to use a replicate design in this situation?

Thank you,
Jo

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
175 visitors (0 registered, 175 guests [including 18 identified bots]).
Forum time: 20:05 CEST (Europe/Vienna)

Young man, in mathematics you don’t understand things.
You just get used to them.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5